Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience-Reference-Cited by-同舟云学术

Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience

Published:2020-12-06 Issue:1 Volume:34 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Bonifati Claudio¹^ORCID,Morrone Aldo²,Cristaudo Antonio¹,Graceffa Dario¹

Affiliation:

1. Department of Clinical Dermatology; Center for the Study and Treatment of Psoriasis San Gallicano Dermatological Institute, IRCCS Rome Italy

2. Scientific Direction, San Gallicano Dermatological Institute IRCCS Rome Italy

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14584

Reference12 articles.

1. Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL‐17, anti‐12/23 and/or anti IL‐23: preliminary data of a real‐life 16‐week retrospective study;Megna M;Dermatol Ther,2020

2. Severe Psoriasis – Oral Therapy with a New Retinoid

3. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment

4. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use

5. Guselkumab versus secukinumab for the treatment of moderate‐to‐severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial;Reich K;Lancet,2019

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort;International Journal of Dermatology;2024-01-05

2. Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis;Frontiers in Medicine;2023-12-14

3. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience;Journal of Clinical Medicine;2023-12-05

4. Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study;Acta Dermato-Venereologica;2023-11-21

5. Extracts from Seseli mairei Wolff attenuate imiquimod-induced psoriasis-like inflammation by inhibiting Th17 cells;Heliyon;2023-07